title: Effect of recombinant human soluble thrombomodulin on clinical outcomes of patients with coagulopathy after hematopoietic stem cell transplantation.
abstract: From 2001 to 2012, 71 individuals with hematological diseases received HSCT in our institution. Of these, 41 developed disseminated intravascular coagulation (DIC) in association with various underlying conditions. The patients who developed DIC after 2008 (n = 23) were treated by recombinant human soluble thrombomodulin (rTM), and the others (n = 11) were treated by either heparin and/or antithrombin III concentrate. Seven patients did not receive any anticoagulant therapy. Of note, treatment for coagulopathy by rTM significantly improved clinical outcomes of patients at day 100 and dramatically prolonged their overall survival (P = 0.044). Taken together, rTM is useful to improve clinical outcomes of transplant recipients with coagulopathy.
authors: Department of Hematology and Respiratory Medicine, Kochi University, Nankoku, Kochi, Japan.
authors: Takayuki
authors: T
authors: Ikezoe
authors: Asako
authors: A
authors: Takeuchi
authors: SungGi
authors: S
authors: Chi
authors: Masato
authors: M
authors: Takaoka
authors: Kazuki
authors: K
authors: Anabuki
authors: Tsukie
authors: T
authors: Kim
authors: Mizu
authors: M
authors: Sakai
authors: Ayuko
authors: A
authors: Taniguchi
authors: Kazuto
authors: K
authors: Togitani
authors: Akihito
authors: A
authors: Yokoyama
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000990:Antithrombin III / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality / Q000473:pathology; D005260:Female; D019337:Hematologic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012995:Solubility; D016019:Survival Analysis; D018180:Thrombomodulin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D011994:Recombinant Proteins; C546931:THBD protein, human; D018180:Thrombomodulin; D000990:Antithrombin III; D006493:Heparin
keywords: recombinant human soluble thrombomodulin; sinusoidal obstructive syndrome; transplantation-associated microangiopathy